Special Issue "Stem Cell Therapy"
QuicklinksA special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: 31 July 2010
Special Issue Editor
Guest Editor
Prof. Dr. Adrian P. Gee
Departments of Medicine and Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Plaza, BCM225, Houston, Texas 77030-3411, USA
Website: http://www.bcm.edu/genetherapy/faculty/gee.html
E-Mail:
Published Papers
Special Issue Information
Submission
All manuscripts should be submitted to pharmaceuticals@mdpi.org with a copy to the Guest Editor. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Planned Papers
Type of Paper: Review
Title: Cellular Vehicles to Deliver Cancer Gene Therapy Vectors
Authors: Camino Latorre-Romero, Clara Diestre, Carolina Beldar-Lopez, Miguel Quintanilla and Pilar Martin-Duque; E-Mails: mquintanilla@iib.uam.es, mpmartind.iacs@aragon.es
Abstract: One of the key problems in cancer gene therapy is the inefficient delivery of therapeutic transgenes to tumor sites, after the systemic injection of the viral vector. For that reason, new vector discovery is extremely important for the improvement of gene therapy results. Mammalian cells have been proposed as new vector systems, but recent advances on stem cell research made them perfect candidates for such a task. Tumors are composed of both malignant and normal cells. As the “benign” cell-types are able to form blood vessels, and stroma, it has been hypothesized that exogenously administrated cells of different kind would preferentially engraft at the stromal tumor site, postulating that exogenous cells could deliver cancer gene therapy vectors to tumors.
Last update: 12 February 2010
